(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 543.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Mereo Biopharma Group's revenue in 2026 is $500,000.On average, 9 Wall Street analysts forecast MREO's revenue for 2026 to be $27,358,142,258, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $57,353,136,967. On average, 7 Wall Street analysts forecast MREO's revenue for 2027 to be $37,931,090,585, with the lowest MREO revenue forecast at $1,355,137,852, and the highest MREO revenue forecast at $87,700,882,519.
In 2028, MREO is forecast to generate $127,341,457,955 in revenue, with the lowest revenue forecast at $22,710,131,158 and the highest revenue forecast at $237,835,471,830.